Abstract
This paper provides an overview on the current developments in the German healthcare market. Rebate contracts between pharmaceutical companies and statutory health insurers (SHIs) have proven to be an effective cost containment measure. Increased price pressure in the generic market has led to significant changes in market shares within months. While international companies with broad product portfolios successfully used this instrument to enter the German market, small- and medium-sized enterprises with a narrow product spectrum often saw a decrease in market share. Moreover, the instrument of rebate contracts replaces early entry strategies and might increase profits via portfolio contracts. An overview is given on the new legislation with respect to prescribers and pharmacists together with a look at the framework of public procurement law. Strategic options for generic companies are presented in the context of this legal framework. In addition, considerations that pharmaceutical companies should take into account before negotiating rebate contracts with SHIs are highlighted.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
